ACCEPT SIMS AI™ · BloomShield CIC

BloomShield-branded research demonstrator

RESEARCH DEMONSTRATOR — SYNTHETIC DATA ONLY — NOT FOR CLINICAL USE

Synthetic-data research demonstration · Mock mode — simulated responses, no live AI · Not for clinical use.

Integrated demonstration

Synthetic data only · Not for clinical use. Administrative decisions never establish diagnostic completion.

Load EXP-0885 · Site E · 15 November 2026

Load the fixed scenario above to follow the demonstration. Other filters and dates retain their own historical context.

Which intelligence is being demonstrated?
  • Model A: trained referral-time prediction evaluated on synthetic data, with a 60-day horizon and historical-cutoff safeguards.
  • Event-triggered review: deterministic navigation intelligence based on documented events; no new probability.
  • Generative AI: model-generated administrative recommendations in safeguarded Live mode. Mock mode uses a deterministic fixture and makes no model call.
  • Model B: proposed future dynamic prediction, not yet trained or implemented; no probability is available.
Uploads

Planned ingestion capabilities — not yet operational. This demonstration uses a fixed synthetic cohort.

  • Direct entry with mobile-friendly forms and future offline capabilities.
  • Validated CSV/Excel imports with schema, chronology and data-quality checks.
  • Secure integrations with existing records, laboratory and appointment systems, potentially using HL7 FHIR.

Programme dashboard

Screening activity and follow-up across the synthetic programme.

Site
Screening modality

Programme activity

Unique participants screened
3,855
Screening encounters
4,541
Diagnostic referrals
866
Outstanding pathways
311

Screening pathway

  1. Screening4,541Encounters
  2. Positive finding1,570Documented findings
  3. Referral866Diagnostic referrals
  4. Follow-up1,030Diagnostic visits
  5. Outcome555Resolved pathways

Stage totals use different units. Pending pathways: 311. Insufficient observation: 0.

Participant insight

Expanded synthetic participant 4792 · EXP-4792Synthetic · Site B

Full participant history through 2026-11-22, across modalities and pathways.

  1. · Screening · VIA · Initial · Programme entry
  2. · Screening result · VIA · VIA positive · Adequate
  3. · Repeat plan · HPV DNA · Prior VIA positive · Scheduled for 2026-04-06
  4. · Diagnostic referral · EXP-4792-T-R
  5. · Contact attempt · Reached
  6. · Diagnostic booking · Initial booking
  7. · Diagnostic visit · Attended
  8. · Diagnosis · Colposcopy · Biopsy collected
  9. · Diagnosis · Histopathology · No high-grade lesion identified
  10. · Surveillance plan · HPV DNA · After clinical assessment · Scheduled for 2026-12-05
  11. · Follow-up disposition · Resolved · EXP-4792-T-R

Referral-time risk

Pathway status at observation · Resolved

Loading prediction…

Observed day-60 outcome · Resolved

Screened participants

3855 matching participants. Select a participant to review their timeline and referral-time risk.

ParticipantSite
EXP-1774 · Expanded synthetic participant 1774Site D — Community Engagement Programme
EXP-1775 · Expanded synthetic participant 1775Site B — Peri-Urban Access Programme
EXP-1777 · Expanded synthetic participant 1777Site D — Community Engagement Programme
EXP-1778 · Expanded synthetic participant 1778Site B — Peri-Urban Access Programme
EXP-1780 · Expanded synthetic participant 1780Site C — Rural Outreach Programme
EXP-1781 · Expanded synthetic participant 1781Site B — Peri-Urban Access Programme
EXP-1785 · Expanded synthetic participant 1785Site D — Community Engagement Programme
EXP-1786 · Expanded synthetic participant 1786Site D — Community Engagement Programme
EXP-1789 · Expanded synthetic participant 1789Site E — Resource-Constrained Navigation Programme
EXP-1791 · Expanded synthetic participant 1791Site B — Peri-Urban Access Programme
EXP-1792 · Expanded synthetic participant 1792Site B — Peri-Urban Access Programme
EXP-1793 · Expanded synthetic participant 1793Site B — Peri-Urban Access Programme
EXP-1798 · Expanded synthetic participant 1798Site A — Urban Referral Hub
EXP-1799 · Expanded synthetic participant 1799Site C — Rural Outreach Programme
EXP-1801 · Expanded synthetic participant 1801Site A — Urban Referral Hub
EXP-1802 · Expanded synthetic participant 1802Site E — Resource-Constrained Navigation Programme
EXP-1806 · Expanded synthetic participant 1806Site B — Peri-Urban Access Programme
EXP-1808 · Expanded synthetic participant 1808Site E — Resource-Constrained Navigation Programme
EXP-1809 · Expanded synthetic participant 1809Site B — Peri-Urban Access Programme
EXP-1810 · Expanded synthetic participant 1810Site E — Resource-Constrained Navigation Programme
EXP-1811 · Expanded synthetic participant 1811Site E — Resource-Constrained Navigation Programme
EXP-1812 · Expanded synthetic participant 1812Site A — Urban Referral Hub
EXP-1815 · Expanded synthetic participant 1815Site D — Community Engagement Programme
EXP-1816 · Expanded synthetic participant 1816Site D — Community Engagement Programme
EXP-1817 · Expanded synthetic participant 1817Site D — Community Engagement Programme

Programme insights

Encounters by modality

VIA
1736
HPV DNA
2166
Cytology
639

Navigation activity

Barrier documented
768
Contact attempt
1272
Navigation intervention
333
Diagnostic booking
1081
Diagnostic visit
1030

Documented barriers

Contact difficulty
247
Transport difficulty
253
Appointment coordination
268

Site and modality select screening encounters. Pathway status limits the screened group to participants with a matching referral. Referral, navigation and barrier totals count events linked to matching pathways.